Nephrology focuses on diagnosing and treating kidney diseases. The kidneys filter waste, balance fluids, regulate blood pressure, and manage acute and chronic conditions.
Send us all your questions or requests, and our expert team will assist you.
The overview and definition of HIV‑associated nephropathy provides essential insight for patients, clinicians, and caregivers navigating this complex kidney condition. HIV‑related kidney disease remains a significant cause of morbidity among people living with HIV, affecting up to 30 % of individuals in advanced disease stages. This page delivers a clear overview and definition of the condition, explains how it develops, outlines typical clinical features, and describes modern diagnostic and therapeutic pathways. Whether you are an international patient planning treatment at Liv Hospital or a healthcare professional seeking a concise reference, the information below equips you with the knowledge needed to make informed decisions.
Liv Hospital’s JCI‑accredited nephrology team combines world‑class expertise with a 360‑degree international patient service, ensuring seamless coordination from initial consultation to post‑treatment follow‑up. The following sections break down the topic into focused areas, each offering a detailed yet accessible explanation.
HIV‑associated nephropathy (HIVAN) is a specific form of kidney injury that occurs directly as a result of HIV infection. The condition is most prevalent among individuals of African descent, reflecting a genetic predisposition linked to APOL1 risk variants. While antiretroviral therapy (ART) has reduced incidence, HIVAN remains a critical concern for patients with uncontrolled viral loads or delayed treatment initiation.
Key points in this overview include:
The definition of HIVAN centers on a collapsing form of focal segmental glomerulosclerosis (FSGS) triggered by direct viral infection of renal epithelial cells. The disease process involves a cascade of cellular events:
Genetic susceptibility, particularly APOL1 risk alleles, amplifies this response, explaining the higher prevalence among individuals of African ancestry.
To visualise the pathogenic steps, the following flowchart‑style list outlines the sequence:
Clinicians use kidney biopsy to confirm the histological pattern, distinguishing HIVAN from other HIV‑related kidney diseases such as immune complex nephropathy. This precise definition guides targeted therapy and informs prognosis.
Patients with HIV‑associated nephropathy often present with a combination of laboratory and symptomatic findings. Early detection hinges on recognising the typical clinical picture:
Diagnostic work‑up includes:
In the overview and definition of diagnostic pathways, Liv Hospital employs a multidisciplinary approach: nephrologists coordinate with infectious disease specialists, radiologists, and pathologists to ensure accurate diagnosis while minimizing invasive procedures when possible.
Effective management of HIV‑associated nephropathy integrates antiretroviral therapy with renal‑protective strategies. The core treatment pillars are:
A comparative table highlights first‑line agents:
Liv Hospital’s nephrology team tailors therapy based on individual viral load, renal function, and comorbidities, ensuring that the definition of treatment aligns with the latest international guidelines.
Long‑term outcomes for HIV‑associated nephropathy have improved markedly with early ART initiation. Prognostic factors include:
Patients achieving sustained viral suppression and optimal blood pressure control often experience stabilisation of kidney function. Conversely, delayed treatment correlates with faster progression to ESRD.
Preventing HIV‑associated nephropathy begins with early HIV diagnosis and prompt ART initiation. Patient education focuses on three pillars:
Liv Hospital provides multilingual educational materials, virtual counselling sessions, and a dedicated patient portal where individuals can track lab results, set medication reminders, and communicate directly with their care team.
Key preventive actions summarised in a checklist:
This overview and definition of prevention empowers patients to actively participate in preserving renal function.
For patients traveling to Istanbul for specialised care, Liv Hospital offers a seamless, 360‑degree service model. Coordination includes:
A workflow diagram (text‑based) illustrates the patient journey:
This comprehensive coordination ensures that the overview and definition of HIV‑associated nephropathy is applied within a global context, delivering world‑class care to international patients.
Liv Hospital combines JCI accreditation, cutting‑edge nephrology expertise, and a dedicated international patient program. Our multidisciplinary teams deliver personalised treatment plans, while our logistics team handles travel, accommodation, and language support, allowing patients to focus solely on recovery.
Ready to take control of your kidney health? Contact Liv Hospital today to schedule a confidential consultation with our HIV‑nephropathy specialists and experience seamless, world‑class care.
Liv Hospital Vadistanbul
Prof. MD. Süleyman Tevfik Ecder
Nephrology
Liv Hospital Bahçeşehir
Asst. Prof. MD. Himmet Bora Uslu
Nephrology
Liv Hospital Bahçeşehir
Prof. MD. Mehmet Taşdemir
Pediatric Nephrology
Liv Hospital Bahçeşehir
Prof. MD. Ozan Özkaya
Pediatric Nephrology
Liv Hospital Ankara
Prof. MD. Hüsnü Oğuz Söylemezoğlu
Pediatric Nephrology
Liv Bona Dea Hospital Bakü
MD. FERHAD ŞİRİNOV
Nephrology
Send us all your questions or requests, and our expert team will assist you.
HIV‑associated nephropathy (HIVAN) is a form of kidney injury that occurs when HIV viral proteins infect podocytes and tubular epithelial cells. This triggers a cascade of cellular damage, resulting in a collapsing pattern of focal segmental glomerulosclerosis (FSGS). The disease is most common among people of African descent due to APOL1 risk alleles. Clinically it presents with rapid loss of kidney function, heavy proteinuria, and can progress to end‑stage renal disease if untreated. Early diagnosis and antiretroviral therapy are essential to halt progression.
The risk of HIVAN rises in patients with high viral loads and low CD4 counts, reflecting uncontrolled infection. Genetic susceptibility, especially APOL1 risk alleles found predominantly in individuals of African descent, markedly increases risk. Additional factors such as late presentation to care, poor adherence to antiretroviral therapy, and co‑existing hypertension or diabetes further predispose patients to kidney injury. Recognising these factors helps clinicians prioritize screening and early intervention.
Initial evaluation includes serum creatinine, estimated glomerular filtration rate (eGFR), urinalysis for proteinuria, and renal ultrasound to rule out obstruction. HIV viral load and CD4 count are also assessed to gauge disease activity. The gold standard is a kidney biopsy, which reveals the characteristic collapsing pattern of focal segmental glomerulosclerosis and helps differentiate HIVAN from other HIV‑related kidney diseases such as immune‑complex nephropathy. At Liv Hospital, a multidisciplinary team reviews these results to confirm the diagnosis while minimizing invasive procedures when possible.
Effective management starts with potent antiretroviral therapy (e.g., integrase inhibitors like bictegravir) to suppress viral replication and reduce direct renal injury. Renin‑angiotensin system blockade with ACE inhibitors or ARBs lowers intraglomerular pressure and proteinuria. Tight blood‑pressure control (target <120/80 mmHg) and lifestyle modifications further protect kidney function. In selected cases, short courses of corticosteroids may be used, but immunosuppression is limited. Advanced disease may require renal replacement therapy, including dialysis or kidney transplantation, with outcomes improving when viral suppression is maintained.
Patients who achieve sustained viral suppression and maintain optimal blood‑pressure control typically experience stabilization of kidney function and a 5‑year renal survival of up to 90 % in low‑risk groups. Conversely, delayed treatment, high proteinuria, low eGFR at diagnosis, and presence of APOL1 risk alleles are associated with faster progression to end‑stage renal disease, with survival dropping to around 40 % in high‑risk categories. Regular monitoring—quarterly labs, annual imaging, and adherence counseling—remains crucial for long‑term outcomes.
BlogHIV NephropathyMay 08, 2026Understand hiv kidney disease symptoms and risks like proteinuria. We offer compassionate care and advanced...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 174 28 17